Wouter Piepers News Today

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

THR-687 is a potent pan-RGD integrin antagonistholding potential as next generation first line therapy for DME Leuven, BE, Boston, MA, US - June 10, 2021 - 07.00 AM CET - Oxurion

Investegate announcements from Oxurion NV, OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting

Press release content from Globe Newswire. The AP news staff was not involved in its creation. OXURION NV Presenting Scientific Data at ARVO 2021 Annual Meeting Oxurion NVApril 30, 2021 GMT Leuven, BE, Boston, MA, US – April 30st, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies with a clinical stage portfolio in retinal vascular disorders. Oxurion NV is announcing the presentation of ...

Investegate announcements from Oxurion NV, OXURION NV to Present at Wet AMD and DME Drug Development Summit

Leuven, BE, Boston, MA, US - April 13th, 2021 - 7.30 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ... Oxurion NVApril 12, 2021 GMT Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relap...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer ... Oxurion NVApril 9, 2021 GMT Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor im...

Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD 04/07/2021 | 11:45am EDT Send by mail : Message : Required fields Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Bru...

Oxurion NV - Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD & Corporate Communications wouter.piepers@oxurion.com (mailto:wouter.piepers@oxurion.com) EU Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com (mailto:thrombogenics@citigatedewerogerson.com) US chris.brinzey@westwicke.com (mailto:chris.brinzey@westwicke.com) About Oxurion Oxurion (Euronext Brussels: OXUR) is a b...